With the Federal Trade Commission (FTC) taking a scalpel to the pharmacy benefit managers (PBMs) of UnitedHealth Group Inc
The FTC's lawsuit, targeting these companies for allegedly inflating insulin prices, could have a major ripple effect across the healthcare industry-and that means stock volatility.
So, which stock looks healthier?
UnitedHealth Group: Big & Bold, But Under The Microscope
UnitedHealth Group's OptumRx unit is at the heart of the FTC's lawsuit, and while UNH's sheer scale as a global leader in healthcare gives it plenty of muscle, it also makes it a big target.
Analysts predict a modest 2.75% price movement over the next 12 months, with a price target range of $591 to $680. UnitedHealth's size could either serve as a shield or an anchor, depending on how the FTC's hammer falls.
For now, it's the heavyweight champ, but will its bulk keep it from dodging regulatory punches?
CVS Health: Retail Resilience Or Regulation Roadblock?
CVS Health, known for its 9,000-plus pharmacy locations and its PBM business Caremark, finds itself in the crosshairs, too.
Its integration with Aetna and recent Oak Street acquisition might help it spread risk, but the complexity of its operations also means more regulatory scrutiny.
Analysts are predicting a price movement of around 6.36%, with a 12-month target of $63. CVS is a diversified player, but being a jack-of-all-trades could make navigating the regulatory maze even trickier.
Cigna: Niche Focus, Bigger Moves?
Cigna, meanwhile, might just be the underdog to keep an eye on. Its PBM arm, Express Scripts, is a major player, but Cigna's more focused approach with self-funded plans and key government contracts could help it pivot more easily than its larger rivals.
Analysts expect a more significant 14.22% price movement for Cigna, with a target range of $400 to $438. Cigna's smaller footprint in the broader health insurance landscape could allow it to sidestep the worst of the regulatory fallout and come out swinging.
Who's Got The Edge?
In this health stock showdown, the winner depends on how well these companies can adapt to the FTC's increasing scrutiny.
UnitedHealth's size gives it strength but might make it a bigger target. CVS has a diversified portfolio but faces risks from its complexity. Cigna, while smaller, seems poised for the most price movement and could be the nimblest in dealing with the regulatory headwinds.
Investors should keep a close eye on how this legal saga unfolds - there's more drama to come!
